Phase I study of an AKT inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer

Kari B. Wisinski, Amye J. Tevaarwerk, Mark E. Burkard, Murtuza Rampurwala, Jens Eickhoff, Maria C. Bell, Jill M. Kolesar, Christopher Flynn, Glenn Liu

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of an AKT inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science